BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8385970)

  • 1. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
    Ardizzoni A; Venturini M; Crinò L; Sertoli MR; Bruzzi P; Pennucci MC; Mariani GL; Garrone O; Bracarda S; Rosso R
    Eur J Cancer; 1993; 29A(5):687-92. PubMed ID: 8385970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.
    Ardizzoni A; Pennucci MC; Danova M; Viscoli C; Mariani GL; Giorgi G; Venturini M; Mereu C; Scolaro T; Rosso R
    Br J Cancer; 1996 Oct; 74(7):1141-7. PubMed ID: 8855989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A; Tjan-Heijnen VC; Postmus PE; Buchholz E; Biesma B; Karnicka-Mlodkowska H; Dziadziuszko R; Burghouts J; Van Meerbeeck JP; Gans S; Legrand C; Debruyne C; Giaccone G; Manegold C;
    J Clin Oncol; 2002 Oct; 20(19):3947-55. PubMed ID: 12351591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
    J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working Party.
    Thatcher N; Anderson H; Bleehen NM; Girling DJ; Lallemand G; Machin D; Stephens RJ
    Eur J Cancer; 1995; 31A(2):152-6. PubMed ID: 7536433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
    Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
    Thatcher N; Girling DJ; Hopwood P; Sambrook RJ; Qian W; Stephens RJ
    J Clin Oncol; 2000 Jan; 18(2):395-404. PubMed ID: 10637255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study.
    Ardizzoni A; Sertoli MR; Corcione A; Pennucci MC; Baldini E; Intra E; Ferrarini M; Rosso R; Mazzanti P; Pistoia V
    Eur J Cancer; 1990; 26(9):937-41. PubMed ID: 2177614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
    Trillet-Lenoir V; Soler P; Arpin D; Bohas C; Riou R; Court-Fortune I; Ecochard D; Perol M; Cordier JF
    Lung Cancer; 1996 Jun; 14(2-3):331-41. PubMed ID: 8794414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
    Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE
    Oncology; 1997; 54(5):363-70. PubMed ID: 9260596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
    Ardizzoni A; Venturini M; Sertoli MR; Giannessi PG; Brema F; Danova M; Testore F; Mariani GL; Pennucci MC; Queirolo P
    Br J Cancer; 1994 Feb; 69(2):385-91. PubMed ID: 8297739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A; Favaretto A; Riccardi A; Danova M; Ghiotto C; Giordano M; Pappagallo G; Comis S; Panozzo M; Chieco-Bianchi L
    Cancer; 1993 Aug; 72(3):697-706. PubMed ID: 8392903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
    Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
    Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.